Novo Nordisk confirms details of massive Athlone investmentNovo Nordisk has announced an investment of €432 million in its facility in Athlone. The investment will facilitate an expansion in its manufacturing facility in Monksland. This tabletting facility will provide significant additional manufacturing capacity for current and future Novo Nordisk weight loss treatments. Tom Quinn, Vice President and Site GM, Novo Nordisk Production Ireland, Athlone stated: “At Novo Nordisk, our purpose is to drive change to defeat serious chronic diseases. "This investment strengthens our ability to serve even more patients and reflects Novo Nordisk’s long-term commitment to the growth and sustainability of the Athlone facility.

Source: Irish Independent March 02, 2026 15:24 UTC